

VIVALIS ANNOUNCES A NEW EB66[®] CELL LINE RESEARCH COLLABORATION

Nantes & Lyon (France) – 4 September 2012 – Vivalis (NYSE Euronext: VLS) announced today that it has signed an evaluation program with a major non-governmental vaccine research institute using Vivalis’s proprietary EB66[®] cell line. The program, performed at Vivalis, will assess the productivity of a new viral vector construct in EB66[®] cells used for the development of a new vaccine destined for a large, unmet need.

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of Vivalis jointly stated, *“This will be the first time EB66[®] cells will have been used to produce such a vaccine and we anticipate a successful launch of this evaluation program. Upon its success, the evolution into a larger collaboration between our two organizations exists in which we eagerly seek to participate. With eight EB66[®] cell line agreements signed since the beginning of 2012, we are very happy to see the increasing world-wide market adoption of Vivalis’s core cell line technology.”*

Financial terms of the agreement were not disclosed.

Next Financial Press Release

October 23rd, 2012, after NYSE Euronext market closing: Third Quarter 2012 Revenues

About Vivalis (www.vivalis.com)

Vivalis (Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. Vivalis’ expertise and intellectual property are leveraged in two main areas:

EB66[®] Cell Line

Vivalis offers research and commercial licenses for its EB66[®] cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP’s, and recombinant proteins (with a focus on monoclonal antibodies having enhanced cytotoxic activity). Through these programs Vivalis receives upfront, clinical, and milestone payments along with royalties on licensees net sales.

VIVA|Screen™ Human Antibody Discovery Platform

Customized solutions for the discovery, development, and production of rare, fully human monoclonal antibodies is offered by Vivalis. Through these programs Vivalis receives upfront, clinical, and milestone payments along with royalties on licensees net sales under both service agreements and partnered programs.

Based in Nantes & Lyon (France) and in Toyama (Japan) Vivalis was founded in 1999 by the Grimaud group (ca. 1,700 employees), a worldwide leader in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Intervet, and SAFB Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE in Toyama.

Vivalis

Listed on Euronext Paris – Compartment C of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indices



This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantees can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's document de référence, changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts

Vivalis

Franck Grimaud, CEO

Email: investors@vivalis.com

NewCap

Financial communications agency

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0) 1 44 71 94 91

Email : vivalis@newcap.fr